Cargando…

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

PURPOSE: This study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: We retrospectively reviewed the clinical data of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Xiaoyong, Chen, Peng, Lan, Fengming, Ma, Li, Jin, Jing, Zhang, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160610/
https://www.ncbi.nlm.nih.gov/pubmed/37152052
http://dx.doi.org/10.3389/fonc.2023.1110281
_version_ 1785037317213257728
author Xiang, Xiaoyong
Chen, Peng
Lan, Fengming
Ma, Li
Jin, Jing
Zhang, Ye
author_facet Xiang, Xiaoyong
Chen, Peng
Lan, Fengming
Ma, Li
Jin, Jing
Zhang, Ye
author_sort Xiang, Xiaoyong
collection PubMed
description PURPOSE: This study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: We retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. RESULTS: The ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. CONCLUSIONS: The addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
format Online
Article
Text
id pubmed-10160610
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101606102023-05-06 The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma Xiang, Xiaoyong Chen, Peng Lan, Fengming Ma, Li Jin, Jing Zhang, Ye Front Oncol Oncology PURPOSE: This study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). METHODS AND MATERIALS: We retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. RESULTS: The ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. CONCLUSIONS: The addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable. Frontiers Media S.A. 2023-04-21 /pmc/articles/PMC10160610/ /pubmed/37152052 http://dx.doi.org/10.3389/fonc.2023.1110281 Text en Copyright © 2023 Xiang, Chen, Lan, Ma, Jin and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xiang, Xiaoyong
Chen, Peng
Lan, Fengming
Ma, Li
Jin, Jing
Zhang, Ye
The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title_full The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title_fullStr The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title_full_unstemmed The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title_short The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
title_sort short-term efficacy and safety of induction chemotherapy combined with pd-1 inhibitor or anti-egfr in locoregionally advanced nasopharyngeal carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160610/
https://www.ncbi.nlm.nih.gov/pubmed/37152052
http://dx.doi.org/10.3389/fonc.2023.1110281
work_keys_str_mv AT xiangxiaoyong theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT chenpeng theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT lanfengming theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT mali theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT jinjing theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT zhangye theshorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT xiangxiaoyong shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT chenpeng shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT lanfengming shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT mali shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT jinjing shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma
AT zhangye shorttermefficacyandsafetyofinductionchemotherapycombinedwithpd1inhibitororantiegfrinlocoregionallyadvancednasopharyngealcarcinoma